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Abstract
Pax3 and Pax7 are paired-box transcription factors with roles in developmental and adult regenerative myogenesis. Pax3
and Pax7 are expressed by postnatal satellite cells or their progeny but are down regulated during myogenic differentiation.
We now show that constitutive expression of Pax3 or Pax7 in either satellite cells or C2C12 myoblasts results in an increased
proliferative rate and decreased cell size. Conversely, expression of dominant-negative constructs leads to slowing of cell
division, a dramatic increase in cell size and altered morphology. Similarly to the effects of Pax7, retroviral expression of Pax3
increases levels of Myf5 mRNA and MyoD protein, but does not result in sustained inhibition of myogenic differentiation.
However, expression of Pax3 or Pax7 dominant-negative constructs inhibits expression of Myf5, MyoD and myogenin, and
prevents differentiation from proceeding. In fibroblasts, expression of Pax3 or Pax7, or dominant-negative inhibition of
these factors, reproduce the effects on cell size, morphology and proliferation seen in myoblasts. Our results show that in
muscle progenitor cells, Pax3 and Pax7 function to maintain expression of myogenic regulatory factors, and promote
population expansion, but are also required for myogenic differentiation to proceed.
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Introduction
The Pax gene family contains nine members characterised by the
presence of a common paired-box domain that directs binding to
specific DNA sequences. Pax genes encode transcription factors that
have important and highly conserved roles during development. In
skeletal muscle, Pax3 and Pax7 have overlapping, but non-redundant
roles in the specification of embryonic muscle progenitors, and
network with the myogenic regulatory factor (MRF) family of
transcription factors comprising Myf5, MyoD, Mrf4 and myogenin
[reviewed in 1]. During the earliest stages of embryonic muscle
development, Pax3 and Myf5 lie genetically upstream of MyoD but in
laterdevelopmental stagesbothMyf5 and MyoD functiondownstream
of Pax3 and Pax7 [2,3]. In C2C12 immortalised myoblasts, Pax7 has
recently been shown to induce chromatin modifications through
association with a histone methyltransferase complex and direct
binding to regulatory regions of the Myf5 locus [4].
In postnatal skeletal muscle, the primary cellular source of
growth and regeneration is the satellite cell [5–7], a quiescent
muscle precursor cell situated beneath the basal lamina that
surrounds each muscle fibre. In response to muscle injury, satellite
cells are activated, proliferate to form a pool of myoblasts, commit
to differentiation and then fuse together to repair or replace
damaged muscle fibres (reviewed, [8]). Pax7 is expressed almost
ubiquitously by quiescent satellite cells and is co-expressed with
MyoD in their proliferating myoblast progeny [9,10]. Pax3 is
transiently detected in proliferating satellite cell-derived myoblasts
[11–13]. Furthermore, in different Pax3 reporter lines, for example
the Pax3
eGFP/+ mouse, activity at the Pax3 locus is reported in a
subset of muscles, in both quiescent and proliferating satellite cells
[14,15]. Pax7 is specifically required for maintenance of postnatal
muscle. In the Pax7
2/2 mouse, satellite cells are present at birth in
near-normal numbers but their population becomes rapidly
depleted during the early postnatal period [15–18]. Myogenin is
an early marker of commitment to differentiation and initiation of
its expression occurs concomitantly with the down regulation of
Pax7, which is subsequently absent from differentiated myonuclei
[9,10,19]. In myoblast cell cultures Pax7 is similarly not expressed
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accompanying population of undifferentiated cells that stops
proliferating, down regulates MyoD and returns to a non-
proliferating state reminiscent of the quiescent satellite cell [10].
The precise influences of Pax7 and Pax3 on myogenic progression
remain a subject of debate. In C3H10T1/2 cells converted to a
myogenic phenotype by transduction with a MyoD vector, it has
been shown that Pax7 and myogenin can regulate each other in a
reciprocal manner, such that overexpression of Pax7 prevents
myogenin induction and overexpression of myogenin causes Pax7
to be down regulated [20]. Accordingly, sustained retroviral
expression of Pax7 causes a delay in myogenic differentiation in
primary myoblasts [21]. Transfection of C2C12 cells [22] or
primary myoblasts [23,24] with Pax3 encoding constructs has
variously been reported to inhibit differentiation [22,23] or to be
compatible with myotube formation [24].
Here, we show that the rate of cell division is influenced by Pax3
and Pax7. High-levels of Pax gene activation increase proliferative
rate and prevents precocious myogenic differentiation. However,
expression of Pax3 or Pax7 dominant-negative constructs results in
a down regulation of Myf5, MyoD and myogenin, and prevents
myogenic differentiation from proceeding. These findings suggest
that in adult muscle stem cells, Pax genes function to promote




C2C12 and NIH 3T3 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen) supplemented
with 10% (v/v) foetal calf serum, 400 mM L-Glutamine (Sigma)
and 1% (v/v) penicillin/streptomycin solution (Sigma). For
differentiation studies, myogenic cells were cultured to confluency,
at which point they began to spontaneously differentiate and fuse
into myotubes. When analysed at least five days later, there were
many large, multinucleated myotubes present.
Single myofibre isolation
Mice were bred, and experimental procedures were carried out,
in accordance with the Animals (Scientific Procedures) Act 1986.
C57 Bl/10 wild type mice (aged 8–12 weeks) were killed by
cervical dislocation and the extensor digitorum longus (EDL)
muscle carefully dissected. Muscles were digested in 0.2%
Collagenase Type 1 and individual myofibres dissociated by
trituration and washed as described in detail elsewhere [25].
Culture of myofibres and satellite cell-derived primary
myoblasts
For suspension culture, myofibres were incubated in plating
medium [DMEM with 10% (v/v) horse serum (PAA Laborato-
ries), 0.5% (v/v) chick embryo extract (ICN Flow), 400 mM L-
Glutamine (Sigma) and 1% (v/v) penicillin/streptomycin solution
(Sigma)] at 37uCi n5 %C O 2. For adherent cultures, isolated
myofibres were placed in 6-well plates (Nunc) coated with 1 mg/
ml Matrigel (Collaborative Research). Plating medium was added
and the cultures maintained at 37uCi n5 %C O 2. After 48 h in
culture, myofibres were removed, and the remaining satellite cell-
derived myoblasts trypsinised and re-plated in Matrigel-coated
LAB-TEKH 8-well chamber slides (Nunc) with growth medium
[DMEM supplemented with 20% (v/v) foetal calf serum, 10% (v/
v) horse serum, 1% (v/v) chick embryo extract and 400 mM L-
Glutamine (Sigma) and 1% (v/v) penicillin/streptomycin solution
(Sigma)].
Retroviral expression vectors
The retroviral backbone pMSCV-puro (Clontech) was modified
to replace the puromycin selection gene with eGFP, to create
pMSCV-IRES-eGFP, which served as the control vector. The
generation of pMSCV-Pax7-IRES-eGFP using murine Pax7d
(accession NM_011039) cDNA (Pax7 RV) has been described
previously [21]. Murine Pax3 cDNA (accession NM_008781) was
cloned in pMSCV-IRES-eGFP to generate pMSCV-Pax3-IRES-
eGFP, producing Pax3 as a bicistronic message with eGFP (Pax3
RV). The Pax7 and Pax3 dominant-negative constructs have the
N-terminus of Pax7 (first 340 amino acids) or Pax3 (374 amino
acids), that directs DNA binding and so target gene selection, fused
in frame with the active repression domain of Drosophila Engrailed,
producing fusion proteins termed Pax7DN and Pax3DN respec-
tively [15]. We previously confirmed that the Pax3DN and
Pax7DN constructs were functional using cells from a Pax reporter
line, P34, in which b-gal is expressed from an nlacZ reporter that is
regulated by multimerized Pax3/7 binding sites [15,26]. Pax7DN
and Pax3DN were cloned in pMSCV-IRES-eGFP, generating
pMSCV-Pax7DN-IRES-eGFP (Pax7DN RV) and pMSCV-Pax3DN-
IRES-eGFP (Pax3DN RV) respectively, used to repress Pax7 or
Pax3 transcriptional targets. Retroviral constructs, together with
an ecotropic packaging plasmid, were transiently co-transfected
into 293T cells to produce non-replicating retrovirus and the
supernatant harvested.
Retroviral infection
A total of 1,000 C2C12 cells, 2,000 NIH 3T3cells or 5,000
primary myoblasts were plated in each well of LAB-TEKH 8-well
chamber slides (Nunc). After 48 h, the medium was replaced with
a 1:1 dilution of 293T retroviral supernatant with 4 mg/ml
polybrene and incubated at 37uC for 3 h, before the cells were
rinsed and placed in fresh medium. For the studies on the effects of
constitutive Pax construct expression on differentiation, myogenic
cells were left to reach confluency, at which point they began to
spontaneously differentiate and fuse into myotubes, and were
analysed five days post-infection. To infect satellite cells associated
with myofibres, they were exposed to a 1:10 dilution of the
supernatant after 24 hours in culture, and the cells were then
analysed 48 hours later. Where used, BrdU was added to the
medium at a final concentration of 10 mM for 2 h prior to fixation.
Clonal proliferation assay
Retroviral infection of C2C12 and NIH 3T3 cells was carried
out in 6-well plates, and cells were then cultured for a further 24 h
before trypsinisation and re-plating at clonal density (50 cells/cm
2)
in LAB-TEKH 2-well chamber slides (Nunc). Retroviral infection
of satellite cells was carried out in myofibre cultures 24 h after
plating. Myofibres were removed 24 h after infection, and the
migrating satellite cell-derived myoblasts were trypsinised and re-
plated at clonal density in chamber slides. After a further 72 h in
culture, cells were fixed, immunostained and the numbers of cells
in distinct eGFP-expressing colonies were counted.
Immunocytochemistry
Cell cultures or myofibres were fixed in 4% paraformaldehyde/
PBS for 10 minutes, permeabilised with 0.5% (v/v) Triton X-100
in PBS and then blocked using 10% (v/v) goat serum and 10% (v/
v) swine serum in PBS. Primary antibodies used were monoclonal
rat anti-BrdU clone BU1/75 (Abcam), monoclonal mouse anti-
myogenin clone F5D (Developmental Studies Hybridoma Bank),
polyclonal rabbit anti-myogenin (Santa Cruz), monoclonal mouse
anti-MyoD clone 5.8A (DakoCytomation), polyclonal rabbit anti-
Pax3/7 in Adult Myogenesis
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Studies Hybridoma Bank), monoclonal mouse anti-Pax3 (Devel-
opmental Studies Hybridoma Bank) polyclonal rabbit anti-GFP
(Invitrogen) and monoclonal mouse anti-MyHC (MF20) (Devel-
opmental Studies Hybridoma Bank). Primary antibodies were
visualised with species-specific or isotype-specific fluorochrome-
conjugated secondary antibodies (Invitrogen) before mounting in
Faramount fluorescent mounting medium (DakoCytomation)
containing 100 ng/ml 4,6-diamidino-2-phenylindole (DAPI).
Western Blotting
Lysates were collected from C2C12 cells either 72 h or 1 week
post-infection in LDS sample buffer (Expedeon) supplemented
with 20 mM dithiothrietol. Lysates were separated by 4–20%
gradient sodium dodecyl sulphate polyacrylamide gel electropho-
resis (RunBlue: Expedeon) and blotted onto nitrocellulose
membranes using the iBlot system (Invitrogen). Membranes were
blocked in 2% non-fat milk PBS with 0.5% Tween-20 and
incubated with the following primary antibodies overnight at 4uC:
monoclonal mouse anti-Pax7 (1:10); monoclonal mouse anti-
MyoD clone 5.8A (1:100) or polyclonal rabbit anti-GFP (1:200),
then washed and incubated with species-matched Horseradish
Peroxidase-conjugated secondary IgG. Protein bands were
visualised using enhanced chemiluminescence (GE Healthcare).
All blots were stripped with Restore Stripping Buffer (Thermo
Scientific) and re-probed with monoclonal mouse anti-b-tubulin
clone E7-c (Developmental Studies Hybridoma Bank: 1:1000) as a
loading control.
Quantitative RT-PCR
Total RNA was isolated using an RNeasy kit (Qiagen) from
infected C2C12 cells 72 h post-infection, and cDNA prepared using
the Quanti-Tect kit (Qiagen). QPCR was performed on an Mx3005P
QPCR system (Stratagene) using Brilliant II SYBR green reagents
with ROX reference dye (Stratagene) with the following primers,
designed using Primer-BLAST (NCBI): Myf5 (F – 59 TGAGGGAA-
CAGGTGGAGAAC39,R–5 9AGCTGGACACGGAGCTTTTA
39); MyoD (F – 59 AGCACTACAGTGGCGACTCA 39,R-5 9
GCTCCACTATGCTGGACAGG 39); myogenin (F – 59 CTA-
CAGGCCTTGCTCAGCTC 39,R–5 9 AGATTGTGGGC-
GTCTGTAGG 39)a n dGapdh (F – 59 GTGAAGGTCGGTGT-
GAACG 39,R–5 9 ATTTGATGTTAGTGGGGTCTCG 39).
Expression levels of Myf5, MyoD and myogenin were normalised to
expression levels of Gapdh control gene and are represented as fold
change over values derived from control RV-infected cultures.
Results show duplicate QPCR analysis from two independent
experiments (n=2+2). Statistical analysis was performed using
Relative Expression Software Tool (REST 2008).
Semi-quantitative RT-PCR analysis for Pax3 and Pax7 was
conducted using Taq polymerase with primers for Pax3 (F – 59
GGGAACTGGAGGCATGTTTA 39,R-5 9 GTTTTCCG-
TCCCAGCAATTA 39) and primers for Pax7 that amplify both
the endogenous and dominant-negative mRNA, Pax7 (F 59 –
CCGTGTTTCTCATGGTTGTG 39,R–5 9 GAGCACTCGGC-
TAATCGAAC 39).
Image capture and quantitative analysis
Images were captured on a Leica DMR microscope using
Metamorph Image analysis software. Cell size was quantified using
SigmaScan Pro. Myotube size was evaluated by measuring a
sequence of minor axes perpendicular to the major axis of each
distinguishable myotube. The average minor axis was calculated as
the mean of a series of axis values taken throughout the length of
each myotube. Images were optimized globally and assembled into
figures using Adobe Photoshop CS3.
Results
The role of Pax3 in myogenesis has mainly been examined
during embryonic development [e.g. 27]. Here we wished to
examine the effects of Pax3 on myogenesis in adult, and used both
primary satellite cells [10] and the C2C12 myogenic cell line,
derived from regenerating adult mouse skeletal muscle [28].
Pax7 is expressed in satellite cells in muscles from throughout
the body [10,16], while the Pax3 locus is active in satellite cells in a
subset of muscles, including many in the forelimb [11,15]. We
were unable to detect endogenous Pax3 protein in any satellite cell
on freshly isolated myofibres from any muscles examined
(including from the forelimb), using a monoclonal mouse anti-
Pax3 antibody (obtained from DSHB) (data not shown). We also
examined Pax3 protein in proliferating C2C12 myoblasts, but
were unable to detect endogenous Pax3 protein at any stage,
including in reserve cells (quiescent-like cells, opting out of
immediate differentiation [29]) (data not shown).
To both investigate cross-regulation between Pax genes in
myogenic cells, and confirm the specificity of the anti-Pax3
antibody for Pax3, we infected low-density cultures of a C2C12
subclone (with low endogenous Pax7 levels) with Pax3 RV or Pax7
RV, which resulted in co-expression of Pax3, or Pax7 respectively,
together with eGFP from the IRES-eGFP in the retroviral
backbone (Figure 1a–d). Pax3 IgG2a monoclonal antibody bound
only to the nuclei of cells infected with Pax3 RV, but not those
infected with Pax7 RV, while the Pax7 IgG1 monoclonal antibody
bound only to the nuclei of cells infected with Pax7 RV and not
Pax3 RV (Figure 1a–d). Therefore, expression of either Pax gene
did not induce expression of its paralogue, and we confirm that the
Pax3 and Pax7 antibodies each have high specificity for their
target protein (Figure 1a–d).
Pax3 and Pax7 regulate the rate of cell division in
myogenic cells
It was noted that bulk cultures infected with Pax3 RV or Pax7
RV appeared to have more cells than those infected with control
RV. To further investigate a potential role for Pax3 and Pax7 in
the control of proliferation rate, C2C12 cells and primary satellite
cell-derived myoblasts were infected with RV and then trypsinised
and re-plated at clonal density. After a further 72 h in culture, cells
were fixed and immunostained and the number of cells per each
eGFP-expressing clone counted. Mean cell number in clones
derived from cells infected with control RV was not significantly
different to that in clones derived from non-infected cells, showing
that although RV are only integrated into actively-dividing cells,
infected cells are a representative sample of the whole prolifera-
tion-competent population. Clones derived from Pax3 RV- or
Pax7 RV-infected C2C12 cells (Figure 1e–g, quantified in j) and
satellite cells (Figure 1l) contained significantly greater numbers of
progeny than clones derived from cells expressing control RV
(p,0.001 quantified in j and l).
In addition to using constitutive expression of Pax3 and Pax7 to
explore the role of these genes, we also used dominant-negative
versions [15,30]. In the Pax3DN and Pax7DN fusion proteins, the
Pax gene sequences directing DNA binding (and so target gene
selection) are fused in frame with the active repression domain of
Drosophila Engrailed, so repress Pax3 or Pax7 transcriptional
targets. Infection with Pax3DN RV or Pax7DN RV dominant-
negative constructs was identified by production of eGFP from
IRES-eGFP in the viral backbone. eGFP+ve infected cells were not
Pax3/7 in Adult Myogenesis
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epitopes are not included in the dominant-negative constructs.
Infection of myoblasts with either Pax3DN RV or Pax7DN RV
dominant-negative constructs resulted in a significant reduction in
the mean number of cells per colony in both C2C12 (Figure 1h
and i, p,0.001 quantified in j) and satellite cell-derived myoblasts
(p,0.001 - Figure 1l). Infected cells attached to the substrate, and
did not have an apoptotic appearance.
C2C12 cells and primary satellite cells were infected with
control RV, Pax3 RV, Pax7 RV, Pax3DN RV or Pax7DN RV,
and then treated with a pulse of BrdU for 2 h immediately before
fixation. When compared with cells infected with the control RV,
infection of cells with any of the other four vectors did not result in
a significant difference between the proportions of cells that were
actively synthesising DNA (Figure 1k and m). Thus, activation or
inhibition of Pax3/Pax7 transcriptional targets does not cause
dividing cells to cease DNA synthesis, or greatly affect the length of
S-phase.
Pax3 and Pax7 can regulate cell size and morphology of
myogenic cells
A surprising and unexpected adjunct effect of constitutive
expression of Pax3 or Pax7, or dominant negative inhibition of
their transcriptional targets, was a rapid and pronounced change
in cell size and morphology. Constitutive expression of Pax3 or
Pax7 resulted in smaller, rounder cells, an effect that was most
pronounced in C2C12 cells when compared to actively dividing
control cells (Figure 1e–g). Conversely, dominant-negative inhibi-
tion of Pax3/Pax7 transcriptional targets resulted in a dramatic
increase in cell size coupled with flatter, more irregular
morphology and frequent doubling of nuclei (Figure 1h9 and i9).
Cell size was quantified using SigmaScan Pro image analysis
software, and revealed that in comparison to cells infected with the
control vector, C2C12 cells (Figure 2a) or satellite cells (Figure 2b)
infected with Pax3 RV or Pax7 RV were significantly smaller,
while cells infected with dominant negative Pax3DN RV or
Pax7DN RV were significantly larger (p,0.0001).
Thus the increased rate of division in myogenic cells
constitutively expressing Pax3 or Pax7 was coupled with a
decrease in cell size. Notably however, neither dominant-negative
vector completely inhibited cell division, and the proportion of
cells actively synthesising DNA was relatively unchanged between
the different groups.
Pax3 stimulates MyoD expression and delays myogenic
differentiation
Exposure of satellite cells to the mitogen-rich tissue culture
environment results in rapid activation of quiescent satellite cells to
co-express MyoD with Pax7 in 95–100% of cells [10]. In low-
density C2C12 cultures, only ,50% of proliferating cells express
MyoD at any given time. We were therefore able to use satellite
cells and C2C12 cells as tools to investigate the effects of
constitutive expression of Pax3, or dominant negative inhibition
of the transcriptional targets of Pax3 and Pax7, in cells with
differing background levels of myogenic transcription factor
expression.
Constitutive expression of Pax3 under low-density culture
conditions led to a significant increase in the number of MyoD-
expressing C2C12 cells (Figure 3p). Pax7 RV infections were
included as controls for Pax3 and Pax7DN RV and gave results
consistent with our previous observations [21]. The proportion of
C2C12 myoblasts expressing myogenin remained unchanged
compared to control-infected cells (Figure 3a–c, quantified in p).
Infection of C2C12 cells with either Pax3DN RV or Pax7DN RV
dominant-negative constructs led to a rapid (within 24 h) and
significant (p,0.0001) reduction in the proportion of cells
expressing either MyoD or myogenin protein (Figure 3d and e,
quantified in p), suggesting that although all C2C12 cells lack
Pax3, Pax transcriptional targets are normally activated.
While retroviral-mediated constitutive expression of Pax3 did not
result in any change in MyoD expression in satellite cells retained in
their niche on an isolated myofibre (Figure 3q), significantly fewer
started to express myogenin after 72 h in culture (Figure 3f–h,
quantified in q). These observations are in accordance with our
previous findings on constitutive Pax7 expression [21]. As with
C2C12cells,infectionofsatellitecellswith Pax3DNRVorPax7DN
RV led to significant reductions (p,0.0001) in the number of cells
expressing either MyoD or myogenin (Figure 3i and j, quantified in
q). Therefore the presence of constitutively expressed Pax3 in
satellite cells can reduce the proportion of cells that initiate
expression of myogenin, and inhibition of Pax3/Pax7 function
results in almost complete abrogation of myogenin expression.
Plated satellite cell-derived myoblasts also exhibited an increase in
the number of cells containing MyoD in the presence of constitutive
Pax3 or Pax7 (Figure 3r), while showing significant inhibition of
myogenin induction in the presence of Pax3, Pax7, Pax3DN and
Pax7 DN, compared to control infected cultures (Figure 3k–o,
quantified in r).
Inhibition of Pax3/Pax7 transcriptional targets prevents
myogenic differentiation
Both the presence of constitutively expressed Pax3 or Pax7, and
inhibition of Pax3 and Pax7 transcriptional targets using the
dominant-negative constructs, delay the induction of myogenin.
We next asked whether this delay was temporary, or if myogenic
differentiation was inhibited. Differentiation and fusion of
myogenic cells into myotubes in vitro can be induced by allowing
cultures to reach confluence. As expected, C2C12 cells or primary
Figure 1. Pax3 and Pax7 regulate the rate of myogenic cell division. Pax3 RV and Pax7 RV were used to infect a subclone of C2C12 with low
endogenous Pax7 levels, to first determine if Pax3 or Pax7 could regulate each other. Pax3 RV-infected cells were only recognized by the anti-Pax3
monoclonal antibody (a) and not by the anti-Pax7 antibody (b), whereas Pax7 RV-infected cells were recognized only by the anti-Pax7 antibody (d)
and not by the anti-Pax3 (c). To determine how Pax3 or Pax7 affects myogenic cell proliferation, C2C12 and satellite cell-derived myoblasts were
infected with control RV, Pax3 RV, Pax7 RV, Pax3DN and Pax7DN, plated at clonal density, cultured and fixed 72 h later. They were then co-
immunostained for either eGFP (green) and Pax3 (red), or eGFP (green) and Pax7 (red), and counterstained with DAPI to identify all nuclei. All cells
present in a clone are shown (e–i). Pax3 and Pax7 RV-infected C2C12 (f and g) and satellite cell-derived myoblast clones produced more cells per
colony compared to control (quantified in j and l). In contrast, constitutive expression of Pax3DN or Pax7DN generated C2C12 clones (h and i) with
significantly less cells (quantified in j) with similar results obtained with satellite cell-derived myoblasts (quantified in l). Despite the different
proliferation rates, constitutive expression of Pax3, Pax7 or their dominant-negative versions did not generally alter the percentage of C2C12 or
plated satellite cells incorporating BrdU 72 h post-infection (quantified in k and m). Interestingly, BrdU labelling (BrdU+ve) of eGFP expressing cells
(eGFP+ve) infected with Pax3DN (h9) or Pax7DN (i9) revealed that many cells had two nuclei (arrowed). Scale bar represents 40 mm (except h9 and i9).
Values are population means6SEM of 15–20 clones from each of 3 independent experiments, where an asterisk denotes significant difference at
p,0.05, while two asterisks denotes significant difference at p,0.0001, from controls using Mann-Whitney.
doi:10.1371/journal.pone.0004475.g001
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cultured to confluence (around 120 h under our experimental
conditions) readily formed large multinucleate myotubes that
expressed Myosin Heavy Chain (MyHC), a marker of sarcomere
assembly during terminal differentiation (Figure 4). Reserve cells
arising in post-differentiated cultures of both C2C12 (Figure 4b)
and plated satellite cell-derived myoblasts were positive for Pax7.
While Pax7 was robustly expressed by reserve cells, we could find
no evidence of the presence of Pax3 protein (Figure 4a). Infection
of C2C12 cells (Figure 4c and d) or satellite cell-derived myoblasts
(Figure 4e and f) with Pax3 RV or Pax7 RV did not prevent the
development of multinucleate myotubes, though in both cases
there was a slight delay (,24 h) in fusion. Immunostaining for
Pax3 or Pax7 confirmed the presence of each protein in many
nuclei of myotubes derived from RV-infected C2C12 and satellite
cell-derived myoblasts (Figure 4c–f) which did not perturb
sarcomere assembly, as shown by the presence of MyHC
(Figure 4g–i and l–n). However, myotubes formed from Pax3
RV- or Pax7 RV-containing C2C12 cells were significantly
thinner than those formed from control RV-infected C2C12 cells,
as determined using measurements taken from the minor axis of
individual myotubes (Figure 2c).
By contrast, infection with Pax3DN RV or Pax7DN RV
dominant-negative constructs blocked differentiation, such that no
myotubes were formed and MyHC was rarely expressed in both
C2C12 (Figure 4j and k) and primary satellite cell-derived cultures
(Figure 4o and p). Therefore, although endogenous expression of
Pax3 and Pax7 is restricted to undifferentiated myogenic cells,
neither factor has a major inhibitory effect on myogenic
differentiation. Indeed, activation of Pax3 and Pax7 DNA targets
is necessary for the differentiation program to proceed.
Effects of constitutive Pax3 and Pax7 on Myf5, MyoD and
myogenin mRNA
In order to better understand the dynamics of myogenic gene
expression in response to constitutively expressed Pax3 and Pax7,
we also examined the mRNA levels. RNA was isolated from
C2C12 cells that had been infected with control RV, Pax3 RV,
Pax7 RV, Pax3DN RV or Pax7DN RV, and then cultured for
72 h. The results of semi-quantitative RT-PCR for Pax3 and Pax7
transcripts confirmed our immunocytochemical data. Pax3 mRNA
was only present at high levels in cultures infected with the Pax3
RV, whereas Pax7 mRNA was detected in all cultures, but was
present at much higher levels in cultures infected with Pax7 RV
(Figure 5a). The Pax7 primers also recognised transcript produced
from the Pax7DN construct, but Western blotting using the Pax7
antibody confirmed that only cultures infected with Pax7 RV
contained high levels of Pax7 protein (Figure 5c). We could not
assess Pax3 protein levels by Western blot due to the unsuitability
of the antibody for this application.
We next used QPCR to compare the relative expression levels
of the myogenic regulatory factors Myf5, MyoD and myogenin.
Constitutive expression of either Pax3 or Pax7 resulted in a
significant increase in Myf5 mRNA levels, whereas expression of
either Pax3DN or Pax7DN resulted in a decrease in Myf5
expression (Figure 5b). We could not assess levels of Myf5 protein
due to the absence of an appropriate antibody. Expression of
Pax3DN or Pax7DN also resulted in significantly reduced levels of
MyoD and myogenin mRNAs (Figure 5b), consistent with immuno-
staining results (Figure 3). Interestingly, whereas our earlier
immunocytochemical data showed that constitutive expression of
Pax3 or Pax7 led to an increased proportion of MyoD-expressing
cells, our QPCR data did not show an increase in MyoD mRNA
(Figure 5b). Western blotting of cell lysates confirmed that
infection of cells with Pax3 or Pax7 RV resulted in an increase
in MyoD protein, whereas infection with retroviruses encoding
Pax3DN or Pax7DN resulted in a decrease in MyoD protein
(Figure 5c). These data suggest that whereas Myf5 and myogenin are
Figure 2. Pax3 and Pax7 can regulate the cell size of myogenic
cells. To examine how altered Pax gene function affected cell size,
C2C12 and satellite cell-derived myoblasts were infected with retroviral
constructs encoding Pax3, Pax7, Pax3DN or Pax7DN, together with
empty vector serving as control. Infected cells were plated at clonal
density, fixed after 72 h, immunostained, counterstained with DAPI and
cell size determined using SigmaScan Pro image analysis software. For
both C2C12 (a) and satellite cell-derived myoblasts (b), constitutive Pax3
or Pax7 expression resulted in significantly smaller cells, while the
presence of Pax3DN or Pax7DN caused the cells to get bigger. Indeed,
even the myotubes formed from Pax3 RV- or Pax7 RV-infected C2C12
myoblasts were significantly smaller than controls (c). Values are
population means6SEM of 17–60 cells/myotubes in total from 3
independent experiments, where an asterisk denotes significant
difference (p,0.0001) from controls using Mann Whitney.
doi:10.1371/journal.pone.0004475.g002
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regulated by a different mechanism, perhaps, for instance, at the
level of protein stability.
Pax3/Pax7 transcriptional targets regulate proliferation
and cell size independently of the myogenic program
We have here provided evidence that Pax3 and Pax7 can
influence the rate of cell division in myogenic cells, and also shown
that these factors can regulate the levels of Myf5 and MyoD:
myogenic regulatory factors normally associated with activated
and proliferating satellite cells. To investigate whether the effects
on cell division and size were related to the myogenic program, we
also used our Pax-encoding retroviruses to infect NIH 3T3 mouse
fibroblasts.
NIH 3T3 cells infected with the control RV did not contain
immunodetectable levels of Pax3 or Pax7 (Figure 6c) and infection
with Pax3 RV or Pax7 RV did not result in myogenic conversion,
as assessed by the absence of MyoD (Figure 6a–b9), myogenin and
MyHC proteins, and a failure to form myotubes (data not shown).
However, we observed effects on cell division and cell size that
were similar to those seen in myogenic cells. When plated at clonal
density, NIH 3T3 cells expressing Pax3 or Pax7 generated
colonies that contained significantly larger numbers of progeny
than colonies derived from cells infected with control RV
(Figure 6c–e, quantified in h). Conversely, NIH 3T3 cells
expressing either Pax3DN or Pax7DN generated colonies that
contained significantly fewer progeny than colonies derived from
cells infected with control RV (Figure 6f–g, quantified in h). The
Figure 3. Pax3/Pax7 transcriptional activity is required for myogenin expression. To test the effects of perturbing Pax3 and Pax7 function
on myogenicity, cells were infected with retroviral constructs encoding Pax3, Pax7, Pax3DN or Pax7DN, together with empty vector serving as control.
Cells underwent further culture and were then co-immunostained for either eGFP (green) and MyoD (red), or eGFP (green) and myogenin (red).
C2C12 cells infected with control RV (a), Pax3 RV (b), Pax7 RV (c), Pax3DN RV (d) and Pax7DN RV (e) and co-immunostained for eGFP and myogenin
120 h after infection. Constitutive Pax3 or Pax7 expression resulted in more infected cells (eGFP+ve) with MyoD, while constitutive Pax3DN or Pax7DN
caused less eGFP+ve cells to co-express MyoD and myogenin (quantified in p after 72 h). Satellite cells were infected with control RV (f), Pax3 RV (g),
Pax7 RV (h), Pax3DN RV (i) and Pax7DN RV (j) while retained in their niche on the myofibre and cultured before co-immunostaining for eGFP (green)
and myogenin (red). The presence of constitutively expressed Pax3 (g) or Pax7 (h) was compatible with myogenin expression (arrows), but there were
reduced numbers of infected eGFP+ve satellite cell progeny containing myogenin (quantified in q). Many infected GFP+ve cells expressing Pax3DN (i
- green - arrow) and Pax7DN (j - green - arrow) did not contain myogenin (i and j - red) (quantified in q). Similar results were obtained when plated
satellite cell-derived myoblasts were infected with control RV (k), Pax3 RV (l), Pax7 RV (m), Pax3DN RV (n) and Pax7DN RV (o) and co-stained for eGFP
(green) and myogenin (red), 72 h post infection (quantified in r). Counterstaining with DAPI was used to identify all nuclei present. Scale bar for each
row equals 40 mm, except for k–o where it represents 100 mm. Values are population means6SEM of at least 3 independent experiments, where an
asterisk denotes significant difference at p,0.05, while two asterisks denotes significant difference at p,0.0001, from controls using Mann-Whitney.
doi:10.1371/journal.pone.0004475.g003
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significantly different between conditions (Figure 6i). As with
myogenic cells, many cells expressing the dominant-negative
constructs exhibited doubling of nuclei (Figure 6f9 and g9).
Moreover, when compared with cells infected with control RV,
constitutive expression of Pax3 or Pax7 caused significant
decreases in the mean cell size of NIH 3T3 cells, while
dominant-negative inhibition of Pax3 or Pax7 transcriptional
targets caused significant increases in cell size (Figure 6c–g9,
quantified in j). Thus, Pax3 and Pax7 can regulate the rate of cell
division and cell size independently of MyoD and of other factors
specific to myogenic cells.
Discussion
Pax gene function has been widely examined in mouse models
and the roles of Pax3 and Pax7 during developmental myogenesis
are relatively well understood [1]. However, mice null for Pax3 die
in utero [31], while loss of Pax7 severely compromises postnatal
muscle development and growth [15–17]. Mouse models in which
Pax3 alleles have been targeted with Pax3DN [3] or the stronger
transcriptional activator, Pax3-FOXO1A [32], die shortly after
birth. Furthermore, Pax3 and Pax7 are also expressed extensively
in neural tissue, and Pax mutant mice exhibit perturbed neural
function, which could potentially have effects on satellite cell
development or function. Satellite cells formed in Pax7-null mice
are rapidly depleted from muscle following birth [15–17], but it is
unknown whether this occurs as a result of defects acquired during
development, or through a direct requirement for Pax7 postna-
tally. To study the role of Pax genes in normal adult satellite cell
function, we therefore used primary satellite cells derived from
wild type mice, in combination with the satellite cell-derived C2
myogenic cell line [28], where necessary.
While Pax7 is expressed by most, if not all, freshly isolated
satellite cells [10,16], we were unable to detect Pax3 protein in
any. This included muscles in which the Pax3 locus has been
shown to be active, such as those of the forelimb and diaphragm
[11,14,15]. It has been shown that Pax3 is transiently detectable
during satellite cell activation, with a possible role in the expansion
of the population mooted [11–13]. Our observations that
constitutive expression of Pax3 or Pax7 causes both primary
satellite cell-derived myoblasts and C2C12 immortalised myoblasts
to increase their rate of cell division, suggests that indeed, Pax7
and Pax3 function to promote expansion of the adult muscle
precursor cell pool, consistent with the roles of these genes during
embryonic development [e.g. 2].
The ability of Pax3 to activate the myogenic program in various
embryonic tissues, including neural cells, and in the pluripotent
P19 stem cell line, is well documented [e.g. 27,30]. However, in
adult-derived cells, there are conflicting reports of the effects of
Pax3, with both an inhibition of myogenic differentiation [22] or
no effects [24], having been recorded. Our observation that
constitutive expression of Pax3 is compatible with differentiation of
primary satellite cells is consistent with a recent report document-
ing efficient differentiation of primary myoblasts after transfection
with a Pax3 vector [24] and our previous observations on Pax7
[21]. Interestingly, alveolar rhabdomyosarcoma is often associated
with a chromosomal translocation that creates a chimeric protein,
PAX3-FOXO1A [33]. Target gene selection in PAX3-FOXO1A
is directed by the Pax3 sequences and expression of this strong
Figure 4. Inhibition of Pax3/Pax7 transcriptional targets prevents myogenic differentiation. To test the effects of perturbing Pax3 and
Pax7 function on the ability of myoblasts to fuse into multinucleated myotubes, C2C12 and plated satellite cell-derived myoblasts were infected with
retroviral constructs encoding Pax3, Pax7, Pax3DN or Pax7DN, together with empty vector serving as control. Cells were then allowed to differentiate
and fuse for 5 days and immunostained. Control RV-infected C2C12 co-immunostained for either eGFP (green) and Pax3 (red) or eGFP (green) and
Pax7 (red) showed that Pax3 was not expressed in reserve cells (a) while Pax7 was (b), with neither protein present in myotubes. C2C12 cells still
efficiently fused into myotubes in the presence of constitutively expressed Pax3 (c) and Pax7 (d), with ectopic, retroviral-driven expression of Pax3 (e)
and Pax7 (f) in the nuclei of multinucleated satellite cell-derived myotubes. Infection of C2C12 cells with control RV (g), Pax3 RV (h), Pax7 RV (i),
Pax3DN RV (j) and Pax7DN RV (k) and co-immunostaining for eGFP (green) and myosin heavy chain (MyHC-red) confirmed that constitutive Pax3 (h)
and Pax7 (i) expression did not perturb myotube formation, in contrast to Pax3DN (j) and Pax7DN (k), which effectively prevented it, with very few
myotubes containing both eGFP and MyHC (yellow). Similar results were obtained when plated satellite cell-derived myoblasts were infected with
control RV (l), Pax3 RV (m), Pax7 RV (n), Pax3DN RV (o) and Pax7DN RV (p) and co-immunostained for eGFP (green) and MyHC (red). Counterstaining
with DAPI was used to identify all nuclei present. All experiments were repeated at least 3 times. Scale bar represents 40 mm.
doi:10.1371/journal.pone.0004475.g004
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myogenin transcription and activate a myogenic program [34],
to the extent of conversion into fully differentiated myotubes [35].
However, since both Pax3 and Pax7 can delay the induction of
myogenin expression, and so differentiation, it is possible that
where inhibitory effects of Pax3 on myogenic differentiation have
been reported, the time of analyses might have fallen within this
period of pronounced delay [22,23]. Whilst in our experiments,
constitutive expression of Pax3 or Pax7 did not prevent expression
of MyHC or fusion into syncytia, the resultant myotubes had a
significantly smaller diameter, showing that ectopic Pax3 or Pax7
restricts myoblast accretion and/or myotube growth. Our results
indicate that the inhibitory effect of Pax3 or Pax7 on myogenic
differentiation may result from an extension of the normal
proliferative phase.
It has been previously reported that dominant-negative
inhibition of Pax3 in P19 pluripotent stem cells prevents the
adoption of the myogenic, but not cardiac, skeletal lineage [30],
demonstrating that dominant-negative constructs can be a useful
tool for examining lineage-specific transcriptional regulation. In
plated myogenic cells from juvenile (3-wk) mice, adenoviral
delivery of Pax3DN or Pax7DN inhibited MyoD but not Myf5,
and did not prevent myogenin induction, although the later stages
of differentiation were not examined [15]. In our experimental
system using defined adult satellite cell-derived myoblasts, or
myogenic cell lines, dominant-negative inhibition of either Pax3 or
Pax7 transcriptional targets resulted in essentially indistinguishable
cell phenotypes: myogenic cells down-regulated Myf5 mRNA and
both MyoD mRNA and protein, and failed to induce myogenin
mRNA or protein and fuse into myotubes.
Dominant-negative constructs also slowed the rate of prolifer-
ation and induced a dramatic increase in cell size. DNA synthesis
(measured by BrdU uptake) was maintained, showing that the cells
were still viable and undergoing cell division. Interestingly, we
observed frequent doubling of nuclei, implying a failure or
retardation of cleavage. This behaviour is analogous to that
previously reported in cells treated with very low doses of the
cleavage inhibitor cytochalasin. Whereas cells treated with high
doses of cytochalasin become binucleate and arrest in G1, cells
treated with very low doses become binucleate but maintain DNA
synthesis and eventually divide [36]. The inhibition of myogenic
differentiation and severe retardation of proliferation that resulted
from dominant-negative inhibition of Pax3/Pax7 transcriptional
targets is not a phenomenon specific to transformed cell lines
because we observed the same effects in primary satellite cell-
derived myoblasts. Similarly, primary myoblasts isolated from
Pax7 null mice also display perturbation of the cell cycle and
consequently, decreased colony size [15,17]. It is possible that the
altered cell morphology caused by the presence of PaxDN
constructs could be attributable to perturbed expression of cell
surface antigens, since Pax3 is known to affect cell surface
properties [37], which may affect cell shape by changed adherence
to the tissue culture substrate.
The paired-domain and homeodomain of Pax3 and Pax7 are
responsible for directing DNA binding, and are highly conserved
between the two proteins. Mouse Pax3 and Pax7 paired domains
differ by 8/128 amino acids, and their homeodomains by only 2/
60 amino acids [38]. In addition, both Pax3 and Pax7 recognise
identical consensus DNA sites in vitro [39,40]. It is therefore likely
that in adult muscle progenitor cells, there is significant overlap
between Pax3 and Pax7 target gene selection, explaining the
similar outcomes of infection with Pax3 and Pax7 RV and of
inhibiting target gene transcription using the dominant-negative
versions. Interestingly, as has been indicated by an earlier study
[20], not all of the observed effects of Pax genes on myogenic
regulatory factors can be attributed to changes in gene expression.
Expression of either Pax3DN or Pax7DN led to decreased levels of
Myf5, MyoD and myogenin mRNAs, consistent with the observed
effects on MyoD and myogenin proteins, and indicating a
requirement for Pax3/7 in postnatal expression of these factors.
However, whereas expression of Pax3 or Pax7 led to increased
levels MyoD protein (as measured either by immunostaining or by
Western blot) there were no significant changes in levels of MyoD
mRNA, suggesting mechanisms other than transcriptional control,
such as increased protein stability, are also operating.
We also analysed Pax3 and Pax7 function in non-myogenic
NIH 3T3 fibroblasts, which do not express these Pax genes, to
determine whether their effects on proliferation rate and cell size
were dependent on the myogenic program. In contrast to the
ability of ectopic PAX3-FOXO1A [34], Pax3 and Pax7 were
unable to induce each other, or myogenic proteins, in NIH 3T3
fibroblasts maintained under expansion conditions, as reported
elsewhere [41] (although specific culture conditions can produce
limited activation of the myogenic program after Pax3 infection
[41]). Pax3 has also been reported to be unable to initiate
myogenesis in the human Saos-2 osteosarcoma cell line [42] and
mouse endothelial cells line BEND3 [41], and Pax7 is unable to
activate myogenesis in the C3H10T1/2 multipotent mesenchymal
cell line [43]. In mesenchymal Saos-2 cells however, constitutive
Pax3 expression was reported to result in a significant reduction in
cell size accompanied by changes in cell morphology [42]. In our
experiments using NIH 3T3 fibroblasts, constitutive expression of
Pax3 or Pax7 resulted in decreased cell size and increased
proliferative rate, and expression of Pax3DN or Pax7DN resulted
in increased cell size, decreased proliferative rate, and not
uncommonly, doubling of nuclei. We do not exclude the possibility
that off-target transcriptional effects contribute to the Pax3DN/
Pax7DN cell phenotype. However, the effects of constitutively
expressing Pax3 or Pax7 demonstrate that these factors are
capable of modulating cell morphology and proliferative rate
independently of their ability to regulate expression of muscle-
specific genes. The recent observations that Pax3 can control
Figure 5. Quantitative analysis of the effects of Pax3 and Pax7 on myogenic gene expression. C2C12 were infected with control RV, Pax3
RV, Pax7 RV, Pax3DN RV or Pax7DN RV and analysed for mRNA (72 h later) and protein levels either 72 h or 1 week later. Semi-quantitative RT-PCR
showed that constitutive Pax7 expression did not induce endogenous Pax3 mRNA expression, while Pax3DN did not down-regulate endogenous
Pax7 mRNA (a – M: DNA ladder; NTC: no template control; amplicon sizes – Pax3: 151 bp; Pax7: 247 bp; Gapdh: 250 bp, representative experiments
shown in duplicate). QPCR analysis of Myf5, MyoD and myogenin expression levels 72 h post-infection demonstrated that constitutive Pax3 or Pax7
expression both increased Myf5 levels, whereas the dominant-negative versions had the opposite effects and decreased Myf5 expression (b). Pax3DN
or Pax7DN also suppressed both MyoD and myogenin expression (b). Data show mean fold change from control RV-infected cells (mean6SEM, from
duplicate measurements from 2 independent experiments n=2+2). Hypothesis testing performed using REST analysis where an asterisk denotes
significant difference at p,0.05, while two asterisks denotes significant difference at p,0.01. Western blot analysis of infected cells showed that
constitutive Pax3 or Pax7 expression increased MyoD protein levels, while the dominant-negative versions both resulted in less MyoD protein being
present (c). Western blotting demonstrated that although the infection rates were similar, each construct produced eGFP with differing efficiencies
from the IRES-eGFP in the retroviral backbone.
doi:10.1371/journal.pone.0004475.g005
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mechanism for how ectopic Pax3 may influence cell division [44].
In melanocyte precursors, Pax3 simultaneously activates
expression of Mitf, a transcription factor critical for melanocyte
development, and competitively inhibits Mitf binding to the
dopachrome tautomerase enhancer which is required for melanin
synthesis by fully-differentiated melanocytes, therefore causing
cells to commit to differentiation but yet remain undifferentiated
Figure 6. Pax3/Pax7 transcriptional targets can regulate proliferation and cell size independently of the myogenic program. To
establish whether the effects on cell proliferation and size were a result of interactions of Pax proteins with myogenic genes, NIH 3T3 fibroblasts were
also infected with either Pax3 RV (a and d), Pax7 RV (b and e), control RV (c), Pax3DN RV (f) or Pax7DN RV (g). Infected cells were plated at clonal
density and analysed 72 h post-infection by co-immunostaining for either eGFP (green) and MyoD (red); eGFP (green) and Pax3 (red); eGFP (green)
and Pax7 (red) or eGFP (green) and BrdU (red), before counterstaining with DAPI. NIH 3T3 fibroblasts did not express Pax3 or Pax7 (c) and constitutive
expression of these proteins (a and b) did not elicit the initiation of the myogenic program, as shown by their failure to induce MyoD (a9-b9). As with
myogenic cells, constitutive Pax3 (d) and Pax7 (e) expression resulted in larger clone sizes, while Pax3DN (f) and Pax7DN (g) had the opposite effect,
and significantly reduced clone size (quantified in h). Infection of NIH 3T3 cells with Pax3DN RV (f9) or Pax7DN RV (g9) followed by a 2 h BrdU pulse
after 72 h, indicated that S-phase length was not drastically altered (percentage of infected cells containing BrdU (BrdU+ve/eGFP+ve) quantified in i).
Cells with double nuclei were present (f9 and g9). Again, as with myogenic cells, constitutive Pax3 and Pax7 also caused NIH 3T3 cells to become
significantly smaller, while the presence of the dominant-negative versions resulted in an increase in mean cell size using SigmaScan Pro (quantified
in j). Scale bar equals 40 mm (except d9 and e9). Values are population means6SEM of 6–20 clones from each of 3 independent experiments, where an
asterisk denotes significant difference at p,0.05, while two asterisks denotes significant difference at p,0.0001, from controls using Mann-Whitney.
doi:10.1371/journal.pone.0004475.g006
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Pax3 and Pax7 play a similar role in myogenic cells, such that
activation of a transcriptional target or targets is required for
progression to differentiation but differentiation is moderately
repressed by promoting proliferation. Consistent with this idea,
Pax7
2/2 satellite cells are specified but exhibit marked defects in
their ability to both proliferate and differentiate [15,17,18]. In
comparison with Pax7, Pax3 appears to be less critical for
postnatal myogenesis, but recent studies have provided evidence
for a role in regulating a population of interstitial myoblasts that
persists in Pax7-null muscle [18]. Our results suggest that any
transient expression of Pax3 with Pax7 in proliferating satellite
cell-derived myoblasts [11–13] may function to amplify transcrip-
tion of common target genes.
Our findings suggest that Pax3 and Pax7 simultaneously drive
proliferation of satellite cell-derived myoblasts and keep them
poised for differentiation in response to appropriate environmental
cues. The ability to maintain lineage-commitment of tissue-specific
stem cells whilst allowing their population expansion is a necessary
aspect of preserving the integrity of differentiated adult tissues.
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